What are the common side effects of Evantumumab/Carestream?

Amivantamab is a bispecific antibody that targets both EGFR and MET receptors. It is mainly used to treat patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. As a new type of targeted drug, it has remarkable efficacy, but there are still certain adverse reactions in clinical application, which is of great significance for patient management and efficacy monitoring.

The most common side effects of evantumumab in clinical trials and postmarketing reports include injection-related reactions, rash, pruritus, and fatigue. Injection-related reactions usually occur during the first dose of administration and manifest as symptoms such as fever, chills, hypotension, rash or urticaria. They are mostly mild to moderate and usually resolve within a few hours after the end of the drug infusion. To reduce injection-related reactions, it is clinically recommended to pre-treat with antihistamines or glucocorticoids before the first dose, and to closely monitor vital signs during the infusion.

Skin-related adverse reactions are also a major concern in clinical practice, including acne-like rash, dryness, itching, and skin abnormalities on the hands and feet. Evantumumab interferes with epidermal cell proliferation and differentiation by inhibiting the EGFR signaling pathway, thereby causing skin side effects. Although generally controllable, such reactions may affect the patient's quality of life and therefore require early prevention and intervention, such as the use of moisturizers, topical anti-inflammatory ointments, or oral antihistamines.

In addition, evantumumab may cause mild to moderate hematological adverse reactions, including decreased white blood cell count, thrombocytopenia, and anemia. Although such side effects are relatively rare, when combined with chemotherapy or used for a long time, blood routine monitoring needs to be regularly monitored and dosage adjustments made if necessary. Other adverse effects include stomatitis, diarrhea, and fatigue, which are usually relieved with symptomatic and supportive treatment.

Reference materials:https://www.rybrevant.com/